Docetaxel Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IA/0058 
A.5.b - Administrative change - Change in the name 
12/09/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IB/0057 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/09/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0056 
B.II.b.3.a - Change in the manufacturing process of 
17/08/2023 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0055 
B.II.e.3.b - Change in test procedure for the 
12/06/2023 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
IB/0054 
C.I.z - Changes (Safety/Efficacy) of Human and 
09/03/2023 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0053 
A.5.b - Administrative change - Change in the name 
13/01/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0052 
B.III.1.a.4 - Submission of a new/updated or 
09/12/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Deletion of certificates 
(in case multiple certificates exist per material) 
IA/0051 
B.II.e.6.b - Change in any part of the (primary) 
14/06/2022 
n/a 
packaging material not in contact with the finished 
Page 2/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product formulation - Change that does not affect 
the product information 
IA/0050 
A.7 - Administrative change - Deletion of 
16/12/2021 
28/11/2022 
Annex II and 
manufacturing sites 
PL 
IAIN/0049/G 
This was an application for a group of variations. 
31/08/2021 
n/a 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0048 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/10/2020 
04/10/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0047 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/01/2020 
21/02/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0046 
B.II.e.7.b - Change in supplier of packaging 
09/12/2019 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IA/0045/G 
This was an application for a group of variations. 
15/07/2019 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0044 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/05/2019 
21/02/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0043/G 
This was an application for a group of variations. 
06/05/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0042/G 
This was an application for a group of variations. 
05/03/2019 
n/a 
Page 4/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
T/0041 
Transfer of Marketing Authorisation 
11/01/2019 
01/03/2019 
SmPC, 
Labelling and 
PL 
IAIN/0040/G 
This was an application for a group of variations. 
12/10/2018 
01/03/2019 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 5/16 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0039/G 
This was an application for a group of variations. 
28/09/2018 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0037/G 
This was an application for a group of variations. 
20/07/2018 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 6/16 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.4 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Deletion of certificates 
(in case multiple certificates exist per material) 
IB/0038 
B.III.1.a.1 - Submission of a new/updated or 
19/07/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0036 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/06/2018 
02/07/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0035 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/01/2018 
02/07/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 7/16 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0034/G 
This was an application for a group of variations. 
21/12/2017 
02/07/2018 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0033 
A.5.b - Administrative change - Change in the name 
29/11/2017 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0032 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/07/2017 
02/07/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0030 
Renewal of the marketing authorisation. 
15/12/2016 
23/02/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
Page 8/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0031 
B.III.1.a.1 - Submission of a new/updated or 
16/12/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IA/0029/G 
This was an application for a group of variations. 
19/05/2016 
n/a 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
II/0026 
B.II.b.4.d - Change in the batch size (including batch 
10/03/2016 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
IA/0028 
A.5.b - Administrative change - Change in the name 
22/02/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Docetaxel Accord in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
Page 9/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0027 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/01/2016 
27/01/2017 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IAIN/0025 
B.III.1.a.3 - Submission of a new/updated or 
14/07/2015 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IA/0024 
B.III.1.a.4 - Submission of a new/updated or 
29/05/2015 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Deletion of certificates 
(in case multiple certificates exist per material) 
IAIN/0023 
B.III.1.a.1 - Submission of a new/updated or 
13/05/2015 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0021/G 
This was an application for a group of variations. 
07/11/2014 
n/a 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.4.z - Change in the batch size (including batch 
size ranges) of the finished product - Other variation 
PSUSA/1152/
Periodic Safety Update EU Single assessment - 
25/09/2014 
n/a 
PRAC Recommendation - maintenance 
201311 
docetaxel 
Page 10/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/07/2014 
03/07/2015 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0019/G 
This was an application for a group of variations. 
12/05/2014 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IAIN/0018 
B.III.1.a.3 - Submission of a new/updated or 
11/04/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0015 
Update of section 4.4 and 4.5 of the SmPC in order 
19/03/2014 
16/05/2014 
SmPC 
to add a warning and update the safety information 
on interactions with CYP3A4 inhibitors further to the 
PRAC assessment of a signal. In addition, some 
inconsistencies have been rectified on the number 
and grade of alopecia adverse reactions in section 
4.8 of the SmPC. Furthermore, the Product 
Information was brought in line with the latest QRD 
Page 11/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
template version 9.0. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0016 
B.II.b.2.a - Change to importer, batch release 
07/03/2014 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0012/G 
This was an application for a group of variations. 
20/11/2013 
16/05/2014 
SmPC and PL 
To update section 4.4 to add warning on cystoid 
macular oedema based on the results of safety 
cumulative reviews conducted by the innovator’s 
MAH and section 4.8 of the SmPC to include cystoid 
macular oedema and hyponatraemia in the list of 
adverse reactions following assessment by the CHMP 
for the originator product Taxotere. The Package 
Leaflet is updated accordingly. In addition the 
product information has been brought in line with the 
latest QRD version 9.0. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 12/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0011 
C.I.8.a - Introduction of or changes to a summary of 
30/08/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
II/0007 
To add an alternative batch size of the finished 
27/06/2013 
n/a 
product. 
B.II.b.4.d - Change in the batch size (including batch 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
IB/0010 
Update of the SmPC for Docetaxel Accord following 
14/06/2013 
16/05/2014 
SmPC, Annex 
assessment of the same changes for the reference 
II and PL 
product, Taxotere. Sections 4.4 and 4.8 of the SPC 
are updated in order to add a warning related to 
respiratory disorders and to include interstitial 
pneumonitis, interstitial lung disease and pulmonary 
fibrosis as new adverse reactions observed the post-
marketing setting following a relevant cumulative 
review of the originator product’s safety database. 
Page 13/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Package Leaflet is updated accordingly. Annex II 
was also updated according to QRD template version 
8.3. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0009 
B.II.e.4.c - Change in shape or dimensions of the 
12/06/2013 
n/a 
container or closure (immediate packaging) - Sterile 
medicinal products 
IB/0005/G 
This was an application for a group of variations. 
22/03/2013 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
IB/0006/G 
This was an application for a group of variations. 
20/02/2013 
n/a 
B.II.b.3.z - Change in the manufacturing process of 
Page 14/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the finished product - Other variation 
B.II.b.3.z - Change in the manufacturing process of 
the finished product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IB/0008 
B.II.e.4.c - Change in shape or dimensions of the 
11/02/2013 
n/a 
container or closure (immediate packaging) - Sterile 
medicinal products 
IB/0003/G 
This was an application for a group of variations. 
21/11/2012 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.III.2.a.1 - Change of specification('s) of a former 
non Pharmacopoeial substance to comply with the 
Ph. Eur. or with a national pharmacopoeia of a 
Member State - AS 
IB/0002 
To extend the shelf-life of the finished product from 
18/09/2012 
29/10/2012 
SmPC 
15 to 24 months. 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0001 
B.II.b.4.z - Change in the batch size (including batch 
22/08/2012 
n/a 
size ranges) of the finished product - Other variation 
Page 15/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 16/16 
 
 
 
 
 
 
